The Blackstone Group offered to acquire a 55% stake in I’rom Group, a provider of clinical trial management services, for $120m. "We are pleased to partner with Mr. Mori and the rest of the management team, and help advance the company in its next phase of growth. We believe we can add tremendous value with our deep healthcare expertise and network. Life sciences is one of our highest conviction investment themes globally, including in Japan, where we have made two marquee investments and built these businesses into market leaders. We are committed to supporting I’rom’s mission of bringing critical medicines and technologies to the market and transforming patients’ lives," Atsuhiko Sakamoto, Blackstone Japan Head of Private Equity.